Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLIANCE: Biktarvy vs DTG + F/TDF in HIV/HBV Co-infection
NCT03547908Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- May 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), hepatitis B (HBV), sponsored by Gilead Sciences. Started May 2018; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03547908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547908.